Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Greater mortality DLCBL patients having CAR-T cell infusion with steroids and/or tocilizumab for CRS

Publish date:: May 15, 2020

Key clinical point: Cytokine release syndrome is a serious adverse event for DLCBL patients receiving CAR-T cell infusions, despite treatment.

Major finding: Patients who received steroids (3.4%), tocilizumab (1.8%) or tocilizumab + steroids (8.4%) for CRS had a higher mortality than those who did not (1.4%).

Study details: Retrospective cohort of 1,570 CAR-T infusion encounters for patients undergoing CAR-T procedures for DLBCL.

Disclosures: There was no funding or conflicts information provided.

Citation:

Harris HA et al. Biol Blood and Bone Marrow Transplantation. 2020; 26(3):S312.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,